Connect
Something new in the treatment arsenal?
AstraZeneca reported positive results from a Phase 3 trial for a breast- cancer treatment, sending its American depositary receipts higher.
Shares of AstraZeneca (ticker: AZN) were up 1.7% to $68.16 in morning trading.
The company said the trial showed that the treatment, datopotamab deruxtecan, showed a significant improvement relative to chemotherapy in terms of progression-free survival. Plans to submit the drug for regulatory approval globally are underway.
Progression-free survival “is defined as the time from random assignment in a clinical trial to disease progression or death from any cause,” according to the National Library of Medicine.
Like
Helpful
HugInterested in more discussions like this? Go to the Breast Cancer Support Group.
Connect
This is a very good news. How about side effects, quality of life? Is it manageable?
-
Like -
Helpful -
Hug
3 ReactionsHello, I am in Montreal and I am in Phase 3 of the trial you are talking about.
The trial is called Tropion 01 for HR+ HER2 - (or low). I started Nov 1, 2022.
To qualify you have to be stage 4 and have already tried a few other lines of treatment. I had been on Kisqali, Afinitor, and Xeloda prior to this trial.
When I started the trial, I had a tumour in my left breast, several lymph nodes under my left arm were impacted, and I had Mets in my hips, my lower spine, my sixth rib, one of my vertebrae‘s and my sternum. Currently the only cancer that can be seen on The CT scan is in three of my lymph nodes, which is significantly smaller.
I imagine we will be hearing more talk about this at the San Antonio symposiu
-
Like -
Helpful -
Hug
15 ReactionsTypo above: should read Verzenio Et al, such as Imbrance and Kisquali.
-
Like -
Helpful -
Hug
1 ReactionI think it’s not “mature” enough data … not enough years to evaluate relative to meds in the field for longer. Even Verzenio Ry al’s do not have “ mature” data.
Looking very promising however. I’m sure it will be a huge topic at the San Antonio Breast Cancer Symposium in December.
-
Like -
Helpful -
Hug
8 Reactions@nlb122 thanks for sharing!
I just looked it up and it's for HR+ HER2 low or negative breast cancer. They also had similar results with it for non-small cell lung cancer. Sounds promising for lots of people. I didn't see any actual data so I wonder how is compares to PFS time achieved with Kisqali, Ibrance and Verzenio? If anyone sees the progression free survival (PFS) time posted, please post here. Thanks!
-
Like -
Helpful -
Hug
10 ReactionsUnfortunately, I have no additional information as this announcement was from a financial resource rather than health care site. I do follow the ASCO post online and under the News heading, it does show FDA approval for 4 new treatments and details for use. The more we know helps us sort thru decisions for the future. Hope this helps a bit.
-
Like -
Helpful -
Hug
7 ReactionsPlease elaborate. TY : )
-
Like -
Helpful -
Hug
1 ReactionWhat type of Breast Cancer?
-
Like -
Helpful -
Hug
1 Reaction